# TNT to Increase the Clinical Complete Response Rate for Distal LARC

> **NCT03840239** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 98 (estimated)

## Conditions studied

- Rectal Cancer
- Rectal Cancer Stage II
- Rectal Cancer Stage III
- Chemoradiation

## Interventions

- **DRUG:** Capecitabine, Oxaliplatin
- **RADIATION:** External beam radiotherapy
- **PROCEDURE:** Surgery
- **OTHER:** Watch and wait strategy

## Key facts

- **NCT ID:** NCT03840239
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-25
- **Primary completion:** 2023-12-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03840239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03840239, "TNT to Increase the Clinical Complete Response Rate for Distal LARC". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03840239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*